title: Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy.
abstract: Gene-corrected patient-specific induced pluripotent stem (iPS) cells offer a unique approach to gene therapy. Here, we begin to assess whether the mutational load acquired during gene correction of iPS cells is compatible with use in the treatment of genetic causes of retinal degenerative disease. We isolated iPS cells free of transgene sequences from a patient with gyrate atrophy caused by a point mutation in the gene encoding ornithine-δ-aminotransferase (OAT) and used homologous recombination to correct the genetic defect. Cytogenetic analysis, array comparative genomic hybridization (aCGH), and exome sequencing were performed to assess the genomic integrity of an iPS cell line after three sequential clonal events: initial reprogramming, gene targeting, and subsequent removal of a selection cassette. No abnormalities were detected after standard G-band metaphase analysis. However, aCGH and exome sequencing identified two deletions, one amplification, and nine mutations in protein coding regions in the initial iPS cell clone. Except for the targeted correction of the single nucleotide in the OAT locus and a single synonymous base-pair change, no additional mutations or copy number variation were identified in iPS cells after the two subsequent clonal events. These findings confirm that iPS cells themselves may carry a significant mutational load at initial isolation, but that the clonal events and prolonged cultured required for correction of a genetic defect can be accomplished without a substantial increase in mutational burden.
authors.affiliation: Morgridge Institute for Research, Madison, WI 53715, USA.
authors.forename: Sara E
authors.initials: SE
authors.lastname: Howden
authors.forename: Athurva
authors.initials: A
authors.lastname: Gore
authors.forename: Zhe
authors.initials: Z
authors.lastname: Li
authors.forename: Ho-Lim
authors.initials: HL
authors.lastname: Fung
authors.forename: Benjamin S
authors.initials: BS
authors.lastname: Nisler
authors.forename: Jeff
authors.initials: J
authors.lastname: Nie
authors.forename: Goukai
authors.initials: G
authors.lastname: Chen
authors.forename: Brian E
authors.initials: BE
authors.lastname: McIntosh
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Gulbranson
authors.forename: Nicole R
authors.initials: NR
authors.lastname: Diol
authors.forename: Seth M
authors.initials: SM
authors.lastname: Taapken
authors.forename: David T
authors.initials: DT
authors.lastname: Vereide
authors.forename: Karen Dyer
authors.initials: KD
authors.lastname: Montgomery
authors.forename: Kun
authors.initials: K
authors.lastname: Zhang
authors.forename: David M
authors.initials: DM
authors.lastname: Gamm
authors.forename: James A
authors.initials: JA
authors.lastname: Thomson
mesh_terms: D002478:Cells, Cultured; D018390:Gene Targeting / Q000379:methods; D055106:Genome-Wide Association Study; D042822:Genomic Instability / Q000235:genetics; D015799:Gyrate Atrophy / Q000201:enzymology* / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D006801:Humans; D009953:Ornithine-Oxo-Acid Transaminase / Q000235:genetics* / Q000378:metabolism*; D039904:Pluripotent Stem Cells / Q000201:enzymology* / Q000473:pathology; D011995:Recombination, Genetic
chemical_list: D009953:Ornithine-Oxo-Acid Transaminase